Abstract:Abstract Inflammasomes are multi-protein signalling scaffolds that assemble in response to invasive pathogens and sterile danger signals to activate inflammatory caspases (1/4/5/11), which trigger inflammatory death (pyroptosis) and processing and release of pro-inflammatory cytokines 1,2 . Inflammasome activation contributes to many human diseases, including inflammatory bowel disease, gout, type II diabetes, cardiovascular disease, Alzheimer’s disease, and sepsis, the often fatal response to systemic infection 3–6 . The recent identification of the pore-forming protein gasdermin D (GSDMD) as the final pyroptosis executioner downstream of inflammasome activation presents an attractive drug target for these diseases 7–11 . Here we show that disulfiram, a drug used to treat alcohol addiction 12 , and Bay 11-7082, a previously identified NF-κB inhibitor 13 , potently inhibit GSDMD pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Moreover, disulfiram, administered at a clinically well-tolerated dose, inhibits LPS-induced septic death and IL-1β secretion in mice. Both compounds covalently modify a conserved Cys (Cys191 in human and Cys192 in mouse GSDMD) that is critical for pore formation 8,14 . Inflammatory caspases employ Cys active sites, and many previously identified inhibitors of inflammatory mediators, including those against NLRP3 and NF-κB, covalently modify reactive cysteine residues 15 . Since NLRP3 and noncanonical inflammasome activation are amplified by cellular oxidative stress 16–22 , these redox-sensitive reactive cysteine residues may regulate inflammation endogenously, and compounds that covalently modify reactive cysteines may inhibit inflammation by acting at multiple steps. Indeed, both disulfiram and Bay 11-7082 also directly inhibit inflammatory caspases and pleiotropically suppress multiple processes in inflammation triggered by both canonical and noncanonical inflammasomes, including priming, puncta formation and caspase activation. Hence, cysteine-reactive compounds, despite their lack of specificity, may be attractive agents for reducing inflammation.

Sennoside A is a novel inhibitor targeting caspase-1

Fused Bicyclic Caspase‐1 Inhibitors Assembled by Copper‐Free Strain‐Promoted Alkyne–Azide Cycloaddition (SPAAC)

A small molecule inhibitor of caspase-1 inhibits NLRP3 inflammasome activation and pyroptosis to alleviate gouty inflammation

Discovery of a Covalent Inhibitor of Pro-Caspase-1 Zymogen Blocking NLRP3 Inflammasome Activation and Pyroptosis

SENP1 Promotes Caspase-11 Inflammasome Activation and Aggravates Inflammatory Response in Murine Acute Lung Injury Induced by Lipopolysaccharide

Coptisine from Coptis chinensis blocks NLRP3 inflammasome activation by inhibiting caspase-1

Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D

Chemical Probing Reveals Insights into the Signaling Mechanism of Inflammasome Activation

Molecular mechanism of pyroptosis and inflammasome activation

The Inhibitor Effect of RKIP on Inflammasome Activation and Inflammasome-Dependent Diseases

Identification of D359-0396 as a novel inhibitor of the activation of NLRP3 inflammasome

Novel role for caspase 1 inhibitor VX765 in suppressing NLRP3 inflammasome assembly and atherosclerosis via promoting mitophagy and efferocytosis

Identification and validation of uterine stimulant methylergometrine as a potential inhibitor of caspase-1 activation

Molecular Basis of Caspase-1 Polymerization and Its Inhibition by a New Capping Mechanism

Caspase-1 Deficiency Modulates Adipogenesis through Atg7-Mediated Autophagy: An Inflammatory-Independent Mechanism

Caspase-1 Inhibition Reduces Occurrence of PANoptosis in Macrophages Infected by E. faecalis OG1RF

Cardiolipin Inhibits the Noncanonical Inflammasome by Preventing LPS Binding to Caspase 4/11 to Mitigate Endotoxemia in Vivo

Inhibition of Lysosomal Cathepsin A and Neuraminidase 1 Interaction by Anti-obesity Cyclic Peptide

Saponins as potential novel NLRP3 inflammasome inhibitors for inflammatory disorders

Sinensetin Attenuated Macrophagic NLRP3 Inflammasomes Formation via SIRT1-NRF2 Signaling

Pharmacological Inhibitors of the NLRP3 Inflammasome